Aug 2026· American Journal of Kidney Diseases· 0 citations· 49 references
Medicine
TL;DR
Elevated BP as a major modifiable risk factor for kidney failure mortality, CKD, and albuminuria is highlighted in this large prospective study in Mexican adults.
Abstract
Rationale
&
Objective
Chronic kidney disease (CKD) is a major cause of death in Mexico and blood pressure (BP) may be an important contributor. This study investigated the associations of BP with CKD, albuminuria, and death from kidney failure.
STUDY
Design
Prospective cohort study.
Setting
&
Participants
133,470 adults aged ≥35 to <85 years without CKD or other chronic disease (except diabetes), recruited from two districts of Mexico City between 1998 and 2004, and who survived ≥5 years after recruitment. A random subset of 9198 underwent additional evaluation 2015-2019.
EXPOSURES
Systolic BP (SBP), diastolic BP (DBP) and hypertension (participant report of taking blood pressure lowering medication or BP ≥140/90 mm Hg).
OUTCOMES
Kidney failure mortality during follow-up, and CKD (self-report and/or eGFR <60 mL/min/1.73m2) and albuminuria at the time of repeat clinical evaluation.
ANALYTICAL APPROACH
Multivariable Cox regression for the association of BP with kidney failure mortality and multivariable logistic regression for the association of baseline BP with CKD and albuminuria at the time of re-evaluation.
Results
Among all participants, SBP showed a continuous "log-linear" association with kidney failure mortality; each 20 mm Hg lower SBP being associated with 24% lower risk at ages 40-84 years (kidney failure death hazard ratio [HR] 0.76, 95% confidence interval 0.69-0.84). The association was stronger among those without diabetes (HR 0.54, 0.45-0.69) than with diabetes (HR 0.90, 0.80-1.01) but the absolute excess risk associated with higher BP was similar in these subgroups. Hypertension accounted for 9% of kidney failure deaths. Among those re-evaluated, 6% had developed CKD and 25% had albuminuria. 20 mm Hg lower baseline SBP was associated with 24% lower odds of both CKD (odds ratio [OR] 0.76, 0.68-0.85) and albuminuria (OR 0.76, 0.68-0.84) at the time of re-evaluation. Results were similar for DBP.
Limitations
Baseline urine samples were unavailable and kidney function trends over time could not be assessed.
Conclusions
This large prospective study in Mexican adults highlights elevated BP as a major modifiable risk factor for kidney failure mortality, CKD, and albuminuria.
In nephrology-referred patients with advanced CKD, achieved SBP around 120–<130 mmHg (near 125 mmHg) was associated with the lowest cardiovascular and mortality risk, while SBP ≥140 mmHg, especially ≥160 mmHg, was consistently associated with higher MACE risk.
Ehab Al-sodany, K. Szummer, Joakim Österman et al.· Clinical Kidney Journal· 0 citations
A U-shaped association observed among individuals receiving antihypertensive treatment suggests that the relationship between BP and cardiovascular risk may be complex in this population, highlighting the potential importance of individualized clinical assessment.
Yuta Suzuki, Masachika Nishikawa, Hidehiro Kaneko et al.· Hypertension Research· 0 citations
Excessive salt intake was associated with adverse kidney outcomes in CKD Stage 3 but not in Stages 4–5, and results suggest that salt restriction may be most beneficial in the early stages of CKD in this population.
Across two large cohorts at-risk for CKD, NHB patients experienced higher MAKE risk, shaped by neighborhood social and structural conditions rather than demographic and clinical characteristics alone.
Kiara N Mayhand, Anna M Zemke, Radica Z. Alicic et al.· American Journal of Nephrolo...· 0 citations
As the first randomized trial to determine whether intensive SBP and LDL-C lowering improve kidney outcomes in advanced CKD, this study could help define optimal targets and inform future guideline recommendations.
Yaerim Kim, Jwa-Kyung Kim, Gang-Jee Ko et al.· Kidney Research and Clinical...· 0 citations
UACR testing was underutilized among patients with diabetes and hypertension, and consistent screening could have identified individuals who would benefit from guideline directed antiproteinuric therapies.
Jian Roushani, Sachin V. Pasricha, L. Dubrofsky et al.· Canadian Journal of Diabetes· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.